INTRODUCTION
Degenerative aortic stenosis (AS) accounts for the majority of native valve disease (1) . Surgical aortic valve (AV) replacement is a treatment option that provides good outcome in the majority of the patients, with good durability of the prosthetic valve (2) . However, a large proportion of patients with severe AS are not referred for, or denied surgery. The Euro Heart Survey on valvuluar heart disease demonstrated that up to 33% of the patients with severe AS did not undergo surgery, although there was an indication (3). Patient's age and (multiple) co-morbidities were the main reasons for denial of surgery (4) . Therefore, there is a need for a less invasive treatment option in older patients with severe AS.
In the past few years, new percutaneous AV implantation procedures have been introduced (5) . Two diff erent types of percutaneous AV prostheses now have CE mark approval in Europe. In addition, European (6) and American (7, 8) recommendations on percutaneous AV implantation have been published. In the present manuscript, the clinical experience with the two diff erent percutaneous AVs will be reviewed. In addition, the role of diff erent imaging modalities in the selection of patients, guidance during percutaneous AV implantation and follow-up will be discussed.
PROSTHESES AND CLINICAL EXPERIENCE
Currently, two diff erent types of percutaneous AV devices are commercially available. The balloon-expandable Edwards SAPIEN valve (Edwards Lifesciences Inc., Irvine, California, USA) and the self-expanding CoreValve Revalving prosthesis (CoreValve Inc., Irvine, California, USA). At present, more than 2500 patients worldwide have been treated with percutaneous AV implantation, and the number of studies reporting the clinical experience and results with percutaneous AV procedures is rapidly growing (Table 1 ). In the following paragraphs, technical aspects of the diff erent prostheses and clinical experience with percutaneous AV implantations will be reviewed.
Balloon-expandable valve
Andersen et al. fi rst tested the balloon-expandable percutaneous AV in an animal model in 1992 (9) . Subsequently, Cribier et al. performed the fi rst human implantation in 2002 (10) . The fi rst generation balloon-expandable valve was entitled Cribier-Edwards valve (Edwards Lifesciences Inc.), whereas at present the Edwards SAPIEN valve (Edwards Lifesciences Inc.) is commercially available (Figure 1 ). This prosthesis incorporates a balloon-expandable stainless steel stent, fabric sealing cuff and bovine pericardial leafl ets. At present, available prosthesis sizes are 23 and 26 mm for aortic annulus diameters between 18 to 22 mm and 21 to 25 mm, respectively. Cribier et al. * multi-center study; AV = aortic valve; AVA = aortic valve area. In the fi rst studies, an antegrade implantation of the valve was performed, using transseptal access to the left atrium and passage through the mitral valve to reach the AV (10) . However, at present a retrograde approach through the femoral artery is used (11) . During the procedure, (13, 14) . Twenty seven patients underwent successful percutaneous AV implantation (23 antegrade, 4 retrograde). The 30-day mortality was 22% (6 of 27 patients), and mean aortic valve area (AVA) increased from 0.60 ± 0.11 cm 2 to 1.70 ± 0.10 cm 2 (p<0.001).
Importantly, this improvement in AVA was maintained up to 24 months follow-up (14) .
After these fi rst trials, the Cribier-Edwards prosthesis and the Edwards SAPIEN prosthesis have been used in numerous studies (Table 1) . Overall, acute procedural success is achieved in 75 to 100% of the procedures, and 30-day mortality ranges between 8 and 50% in the published studies. In a large study using the retrograde approach, Webb et al. treated 50 AS patients (mean age 82 ± 7 years, 45 patients in New York Heart Association (NYHA) functional class III or IV) (15) . A Cribier-Edwards valve was successfully implanted in 43 of the 50 patients (86%). Interestingly, a clear learning curve was observed when comparing the fi rst 25 patients with the second 25 patients. Procedural success increased from 76% in the fi rst 25 patients Importantly, a randomized trial using the Edwards SAPIEN valve is currently comparing percutaneous AV implantation against surgical AV replacement (objective: demonstrating non-inferiority of the percutaneous prosthesis) and medical therapy (objective: demonstrating superiority of the prosthesis) ( Figure 2 ). The primary endpoint in the two arms is mortality at 12 months follow-up, with secondary endpoints that focus on long-term adverse cardiovascular events composite, valve performance and quality-of-life indicators (17) . The results of this fi rst randomized trial with percutaneous AV implantations are eagerly awaited.
Self-expanding valve
The CoreValve Revalving system TM (CoreValve Inc.) consists of a tri-leafl et bioprosthetic porcine pericardial tissue valve, mounted and sutured in a self-expanding nitinol alloy stent ( Figure 1 ). The device is constrained within a delivery sheath, and expands to its predetermined shape when the sheath is withdrawn. It has a specifi c design consisting of three distinct parts: The lower portion of the prosthesis has high radial force to expand and avoid recoil. The middle portion includes the pericardial tissue valve and is constrained to avoid coronary occlusion. The upper part is fl ared to center and fi x the prosthesis in the ascending aorta. At present, the third generation CoreValve Revalving system is commercially available. The size of the delivery system has gradually declined from a 25F and 21F system (fi rst-and second-generation, respectively) to the currently available third-generation 18F system. Two diff erent sizes are currently available: a 26 mm prosthesis (aortic annulus diameter 20 -24 mm) and a 29 mm prosthesis (aortic annulus diameter 24 -27 mm). The CoreValve prosthesis is implanted retrograde through the femoral artery. While in the fi rst series the prosthesis was implanted under general anesthesia with a cardiac assist device, extracorporal membrane oxygenation or a full-bypass support (18) , at present local anesthesia combined with mild systemic sedative/analgesic medication is used without cardiac assist or full-bypass support (19) . After balloon valvuloplasty, the device is positioned under fl uoroscopy guidance. Retraction of the outer sheath allows deployment of the self-expanding prosthesis. Postdilatation of the prosthesis can be performed if deemed necessary, depending on the position of the prosthesis and the presence of aortic regurgitation (19) . (19) . In this nonrandomized, prospective study, a total of 136 patients were included. Ten patients were treated with fi rst-generation devices, 24 patients with secondgeneration and 102 patients with third-generation devices. At baseline, mean AVA was 0.67 ± 0.9 cm 2 and mean logistic EuroSCORE was 23.1 ± 15.0 % in the overall study population.
Overall procedural success rate increased signifi cantly with the new generation devices from 70.0% and 70.8% to 91.2% for fi rst-, second-and third-generation prostheses, respectively (p=0.003). Interestingly, periprocedural mortality decreased using newer devices from 10% (fi rst-generation) to 8.3% (second-generation) to 0% (third-generation). Overall 30-day mortality for the three generations was 40%, 8.3% and 10.8%, respectively. Pooled data demonstrated a signifi cant improvement in NYHA functional class (from 3.3 ± 0.5 to 1.7 ± 0.7, p<0.001), without a diff erence between the 3 generations. Importantly, NYHA functional class and mean pressure gradient remained stable up to 12 months follow-up in all 3 generations. This largest single-center experience with three generations CoreValve prostheses demonstrates that the use of the latest generation prosthesis is associated with an improved procedural and mid-term outcome (19) .
In addition, the results of a multi-center registry with the third-generation CoreValve Revalving system have recently been reported (22) . A total of 646 patients from 51 centers were included in the registry. It was a high risk elderly population (mean age 81 ± 7 years) with a poor functional class (85% of the patients in NYHA class III or IV), and a high logistic EuroSCORE (mean 23.1 ± 13.8%). Procedural success was achieved in 628 of the 646 patients (97.2%).
All-cause 30-day mortality was 8%, and the combined end-point of procedural-related death, stroke or myocardial infarction was reached in 60 patients (9.3%). After successful implantation, mean pressure gradient decreased from 49 ± 14 mmHg to 3 ± 2 mmHg (22) . This large registry confi rms the results of earlier studies, and demonstrates the safety, feasibility and effi cacy of the CoreValve Revalving system.
Valve-in-valve procedure
The concept of a percutaneous AV implantation in an existing AV prosthesis ('valve-in-valve') has recently been introduced. The feasibility was demonstrated in an animal model by Walther et al. (23) . Afterwards, the valve-in-valve concept has been successfully applied in patients with degenerated aortic bioprostheses (24, 25) . It may be of great value in these patients, since re-operation for degenerated xenografts is challenging, and is associated with an increased mortality risk as compared with fi rst isolated AV replacement (26) .
Furthermore, the valve-in-valve concept can be used during fi rst percutaneous CoreValve prosthesis implantation, in case of suboptimal implantation of the prosthesis (19) . Good function of the prostheses and durability of the valve-in-valve has been demonstrated up to three years follow-up (27) . Recently, a multi-center study demonstrated that in up to 2.6% of fi rst CoreValve prosthesis implantation procedures, a valve-in-valve procedure is performed (22) .
However, it should be performed with caution because future access to the coronary ostia may be limited by the two overlying nitinol frames of the prostheses.
SELECTION OF PATIENTS
The selection of patients for percutaneous AV implantation involves several critical steps. In general, a multi-disciplinary team, including cardiologists, surgeons, anesthesiologists and imaging specialists, should decide if patients are eligible for percutaneous AV implantation.
Recently, two position statements on the use of percutaneous AV procedures have been published, that provide important information on the patient selection procedure (6, 8) . A summary of the European statement (endorsed by the European Association of Cardio-Thoracic Surgery and the European Society of Cardiology) is provided in Table 2 .
One of the fi rst steps in the selection procedure is the assessment of AS severity. At present, percutaneous AV implantation is only recommended in symptomatic patients with severe AS. The surgical risk, life expectancy, and quality of life should also be assessed. Preferably, the surgical risk is determined using a combination of clinical judgement and multiple risk scores, such as the logistic EuroSCORE, the STS Predicted Risk of Mortality score, or Ambler score (6) . When patients are deemed inoperable due to a high surgical risk, a percutaneous procedure can be considered.
Finally, the feasibility of a percutaneous procedure and contraindications should be assessed in the potential candidates (Table 2) . Typically, coronary anatomy, the aortic annulus and the peripheral vessels are evaluated. For this purpose, various imaging modalities are available. These modalities and their relative merits will be reviewed in the following paragraphs. 
IMAGING IN PERCUTANEOUS AORTIC VALVE IMPLANTATION
Various imaging modalities are available for the selection of patients, performing percutaneous AV implantation, and for follow-up after the procedure. An overview on the role of various imaging modalities in percutaneous AV implantation procedures is provided in Table 3 . Whereas transthoracic echocardiography (TTE), multi-slice computed tomography (MSCT), and magnetic resonance imaging (MRI) are valuable imaging techniques before and after the procedure, transesophageal echocardiography (TEE) is mainly used during the actual implantation procedure.
The various processes and imaging modalities will be reviewed in the following paragraphs
Patient selection
The selection of candidates for percutaneous AV implantation involves a number of critical steps. The diff erent imaging modalities can assist in the selection process by providing important information on the AV, coronary arteries and vascular structures. First, the severity of AS should be assessed. Both TTE and TEE are the preferred tools to assess the severity of AS (1).
However, recent reports have suggested a good correlation between echocardiography and both MSCT (28) and MRI (29) to assess AVA with planimetry.
In addition, the exact anatomy of the AV should be assessed. Echocardiography, MSCT and MRI all can help to distinguish between a bicuspid and a tricuspid AV. It has been suggested that a bicuspid AV may result in a higher incidence of stent misdeployment and peri-stent leakage All modalities can be used AS = aortic stenosis; AV = aortic valve; CAD = coronary artery disease; LV = left ventricular; MSCT = multi-slice computed tomography; TEE = transesophageal echocardiography; TTE = transthoracic echocardiography. (30) . Therefore, at present it is not recommended to perform percutaneous AV implantation in bicuspid AV (6) . Furthermore, the exact location and severity of AV calcifi cations and the presence of bulky AV leafl ets should be assessed. Before the implantation procedure, MSCT may be the preferred tool to identify AV calcifi cations (19) . A severely calcifi ed AV may result in the inability to cross the native valve with the catheter. Bulky leafl ets and calcifi cations on the free edge of the leafl ets may increase the risk of occlusion of the coronary ostia during AV implantation (15) . Therefore, the extent and exact location of calcifi cations should be carefully assessed before the implantation procedure (Figure 3 ).
The assessment of coronary anatomy is also important in the selection process. Conventional coronary angiography should be performed to exclude the presence of signifi cant coronary artery disease (6) . Although conventional angiography remains the 'gold standard' , non-invasive evaluation of coronary artery disease may be performed with MSCT as well. This technique also allows detailed, three-dimensional evaluation of the relation between the coronary ostia and the AV leafl ets. This may be important to avoid coronary occlusion during AV
implantation. It has been demonstrated that the relation between the aortic annulus, the coronary ostia and leafl ets is highly variable. In a cohort of 169 patients undergoing MSCT scanning, it was noted that the distance between the aortic annulus and the coronary ostia was smaller than the length of the AV leafl ets in up to 49% of the patients (31) . In these patients, the risk of coronary occlusion during percutaneous AV implantation may be increased. Therefore, both invasive and non-invasive evaluation of coronary anatomy can provide important information for the selection of candidates for percutaneous AV implantation.
The assessment of aortic annulus diameters is of utmost importance for correct prosthesis sizing. Various prosthesis sizes for the balloon-expandable and self-expanding prostheses are available for a wide range of annulus diameters. However, at present no gold-standard is available for the exact measurement of the aortic annulus diameter. Typically, TTE is used to assess the aortic annulus diameter (Figure 4, panel A) . However, it may underestimate the diameter when compared with TEE (32). Importantly, with both techniques the basal attachments of the leafl ets are used as landmark points, potentially underestimating the true/ full aortic annulus diameter (33) . In contrast, three-dimensional echocardiography, MRI and MSCT allow a threedimensional, multi-planar reconstruction of the aortic annulus ( Figure 4 , panels B and C). This may result in a more accurate measurement of the aortic annulus diameter.
Furthermore, the anatomy of the aorta and peripheral vasculature should be assessed.
Conventional angiography is the preferred imaging modality. However, MSCT and MRI may also provide the necessary information. A transapical approach is preferred over the transfemoral approach in patients with a severe angulation of the aortic arch, or the presence of atheroma in the aorta. In patients with severe calcifi cations and/or tortuosity of the femoral vessels, or small vessel diameters (typically < 6 to 9 mm), a transfemoral approach is contraindicated, because of the high risk of vascular complications. Finally, contraindications such as the presence of atrial or ventricular thrombi, and a very poor left ventricular ejection fraction should be assessed.
Aortic valve implantation
During the AV implantation procedure, a combination of fl uoroscopy/ angiography and TEE is typically used (8) . Rather than replacing each other, these techniques are complimentary during the AV implantation. Contrast aortagraphy can be used for fi nal assessment of the aortic For the assessment of coronary patency, coronary angiography should be performed after prosthesis implantation ( Figure 5 , panel C). Acute coronary occlusion is a serious, but rare complication. Interestingly, it has been demonstrated that correct positioning of the prosthesis even allows coronary intervention after percutaneous AV implantation (34) .
Various complications have been reported after percutaneous AV implantation, mainly related to vascular access and thromboembolic complications. In addition, new atrioventricular block may occur in up to 6% of the patients (35) . In addition to fl uoroscopy, TEE may help in the Finally, intracardiac echocardiography and novel three-dimensional TEE may be helpful in guidance of percutaneous AV implantation. Three-dimensional TEE may allow a more precise evaluation of the AV, and may improve spatial orientation and prosthesis positioning (37) .
However, more studies are needed to fully understand the exact value of these techniques in percutaneous AV implantations.
Follow-up
In addition to complications and conventional outcome parameters (such as mortality, stroke, major cardiac events), prosthesis function and position should be assessed during follow-up (38) . For this purpose, TTE is the most commonly used technique (39) . In most studies, the AVA and mean pressure gradient are used to quantify AV function (Table 1 ). In addition, aortic regurgitation should be assessed.
The exact position of the prosthesis and the relation between the stent and the coronary arteries can be assessed with MSCT. This technique may be preferred over TTE because it is less hampered by artifacts, and has a high spatial resolution. In addition, it allows a more precise evaluation of prosthesis deployment and diameters (40) . Examples of MSCT images after percutaneous AV implantation are shown in Figure 6 . 
CONCLUSIONS
Percutaneous AV implantation is a promising technique for highly symptomatic patients with severe AS. Several studies have demonstrated good results for both the balloon-expandable and self-expanding valves. A critical selection of potential candidates, including clinical evaluation, assessment of surgical risk and feasibility of the procedure is needed. Several imaging modalities are available for patient selection, procedural assistance and follow-up.
